Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Cellectar Biosciences, Inc. (CLRB) had Stock-Based Compensation of $1.70M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-4.44M |
|
-- |
|
-- |
|
$4.85M |
|
$-4.85M |
|
$0.41M |
|
$-4.44M |
|
$-4.74M |
|
$-4.44M |
|
$-4.44M |
|
$-4.44M |
|
$-4.74M |
|
$-4.85M |
|
$-4.80M |
|
3.16M |
|
3.16M |
|
$-1.41 |
|
$-1.41 |
|
| Balance Sheet Financials | |
$13.62M |
|
$0.60M |
|
$1.01M |
|
$14.63M |
|
$4.91M |
|
$0.34M |
|
$1.72M |
|
$6.63M |
|
$7.48M |
|
$8.00M |
|
$8.00M |
|
3.19M |
|
| Cash Flow Statement Financials | |
$-18.77M |
|
-- |
|
$8.04M |
|
$23.29M |
|
$12.55M |
|
$-10.73M |
|
|
Stock-Based Compensation |
$1.70M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.77 |
|
-- |
|
-- |
|
0.04 |
|
0.04 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-18.77M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-59.44% |
|
-55.57% |
|
-30.38% |
|
-53.33% |
|
$2.51 |
|
$-5.94 |
|
$-5.94 |
|